Frequently asked questions

Side effects of AJOVY

HALO Phase 3 Clinical Trial

The most common adverse reactions reported in ≥2% of patients were injection-site reactions (including injection-site pain, injection-site induration, and injection-site erythema).1

  • <1% of patients experienced constipation vs <1% for placebo2
  • <1% of patients experienced hypertension vs <1% with placebo2
  • ≤2% of patients discontinued due to adverse events in the AJOVY and placebo treatment arms2
  • <1% of patients in both phase 3 trials developed antibodies to AJOVY1

Long-Term Extension study—continuation of the HALO trials*

The most common adverse reactions reported by >6% of patients were injection-site reactions (including injection-site induration, pain, erythema, hemorrhage, and pruritus).3

  • No new safety signals were identified2
  • 6% of patients discontinued due to lack of efficacy or adverse events2
  • Discontinuation rates were comparable for both quarterly (7%) and monthly (5%) dosing2
  • The primary purpose of the Long-Term Extension study was the collection of long-term safety data. Therefore, the study was not placebo controlled.

Please read full Important Safety Information, and full Prescribing Information.

See the safety profile in clinical trials for AJOVY